使用GLP-1激动剂对微血管和宏血管并发症的相对影响
Efeturi M Okorigba1, Kehinde H Jinadu2, Oto-Obong J Utuk3
1Internal Medicine, West Virginia University, Morgantown, USA.
Cureus
|October 28, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 的使用与美国成年人患微血管并发症的几率更高有关. 对于大血管并发症没有发现任何显著的联系,这表明需要进一步研究.
科学领域:
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
- 公共卫生 公共卫生
背景情况:
- 糖尿病和肥胖是血管并发症的主要原因.
- 葡萄糖类-1受体激动剂 (GLP-1RA) 对血管结果的影响需要进一步阐明.
- 了解GLP-1 RA的影响对于管理糖尿病及其并发症至关重要.
研究的目的:
- 研究GLP-1 RA使用与美国成年人微血管/宏血管并发症之间的关联.
- 为了比较GLP-1 RA使用者与非使用者的血管并发症调整后的几率.
- 在美国人口中识别与血管并发症相关的危险因素.
主要方法:
- 分析国家健康和营养检查调查 (NHANES) 数据 (2011-2018).
- 对人口统计,社会经济和临床因素进行调整的调查加权后勤回归模型.
- 微血管并发症 (白内障,糖尿病视网膜病变) 和宏血管并发症 (心肌梗塞,中风,冠状动脉疾病) 的定义.
主要成果:
- GLP-1 RA使用与微血管并发症的几率增加有关 (OR 2.29,p=0.037).
- 在GLP-1 RA使用和宏血管并发症之间没有发现显著的关联 (OR 1.27,p=0.478).
- 年龄较大,BMI较高,收入较低和吸烟是血管并发症的独立危险因素.
结论:
- GLP-1 RA的使用显示了与更高的微血管并发症几率的联系,可能是由于指示的混.
- 没有观察到与大血管并发症有显著的关联.
- 建议进行长度研究,以澄清GLP-1RA使用与并发症风险之间的时间关系.
相关概念视频
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
521
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K


